Ionis pharmaceuticals, inc. (IONS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Sep'09Jun'09
Revenue:
Revenue

958,752

1,122,599

821,032

798,535

752,469

599,674

575,353

548,272

542,798

514,179

532,892

525,505

451,702

372,776

237,842

176,036

257,994

283,703

316,993

311,935

248,583

214,161

171,548

151,070

132,086

147,285

124,910

112,926

122,174

102,049

114,579

123,691

101,174

99,086

93,103

101,014

99,694

108,473

108,824

111,192

0

0

0

Expenses:
Cost of products sold

5,891

4,384

5,192

4,225

2,861

1,820

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sa

476,223

465,688

430,400

421,289

416,954

414,604

429,438

414,397

396,073

374,644

347,510

351,927

345,994

344,320

344,498

348,375

338,809

322,292

288,915

261,493

252,750

241,751

231,228

215,802

199,169

184,033

169,361

160,252

158,056

158,458

162,919

166,292

161,866

157,397

149,511

144,303

147,418

145,160

139,659

137,089

0

0

0

Selling, general and administrative

293,417

286,644

269,427

278,103

269,190

244,622

224,269

182,345

138,464

108,488

80,824

64,224

51,731

48,616

43,755

42,318

40,269

37,173

30,820

26,539

23,226

20,140

17,988

16,948

15,875

14,918

13,476

13,142

12,962

12,515

13,081

13,090

12,755

12,789

11,933

11,683

11,860

11,669

12,060

12,878

0

0

0

Total operating expenses

775,531

756,716

705,019

703,617

689,005

661,046

653,707

596,742

534,537

483,132

428,334

416,151

397,725

392,936

388,253

390,693

379,078

359,465

319,735

288,032

275,976

261,891

249,216

232,750

215,044

198,951

182,837

173,394

171,018

170,973

176,000

179,382

174,621

170,186

161,444

155,986

159,278

156,829

151,719

149,967

0

0

0

Income (loss) from operations

183,221

365,883

116,013

94,918

63,464

-61,372

-78,354

-48,470

8,261

31,047

104,558

109,354

53,977

-20,160

-150,411

-214,657

-121,084

-75,762

-2,742

23,903

-27,393

-47,730

-77,668

-81,680

-82,958

-51,666

-57,927

-60,468

-48,844

-68,924

-61,421

-55,691

-73,447

-71,100

-68,341

-54,972

-59,584

-48,356

-42,895

-38,775

0

0

0

Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,406

-2,418

-2,804

-3,674

-3,554

-2,796

-3,340

-6,249

-6,879

0

0

0

-

-

Investment income

50,542

52,205

50,490

47,317

38,719

30,187

19,333

12,181

9,509

8,179

9,116

7,294

6,295

5,472

5,142

5,537

4,989

4,377

3,826

3,117

2,870

2,682

2,689

2,448

2,366

2,085

1,758

1,732

1,620

1,844

2,003

2,170

2,309

2,414

2,676

2,877

3,120

3,370

4,020

4,922

0

0

0

Interest expense

48,159

48,768

46,859

46,139

45,450

44,789

44,119

43,662

44,327

44,752

43,900

42,821

40,668

38,795

38,212

37,699

37,201

36,732

34,688

30,453

26,287

22,209

19,787

19,656

19,503

19,355

19,287

20,357

20,768

21,152

21,442

20,278

18,496

16,732

15,021

13,586

13,410

13,232

13,021

12,838

0

0

0

Gain on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,256

445

617

1,717

2,378

3,519

3,344

2,506

1,465

4,467

4,485

4,517

4,182

182

149

-21

-713

-1,038

1,589

0

0

0

Gain on investment in Regulus Therapeutics Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on early retirement of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other expenses

-638

-686

-369

-251

-161

-182

-2,990

-5,109

-5,154

-3,548

-703

1,438

1,438

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income (loss) before income tax benefit (expense)

163,101

346,769

119,275

95,845

56,572

-76,156

-103,254

-89,873

-36,524

-16,763

54,523

68,406

14,183

-57,466

-183,481

-226,608

-133,085

-87,906

-1,202

9,296

-38,341

-54,391

-93,786

-98,271

-98,378

-66,558

-53,848

-62,430

-52,330

-74,587

-83,581

-72,118

-88,791

-84,790

-78,649

-64,221

-71,493

-61,159

-59,292

-50,530

0

0

0

Income tax benefit (expense)

9,207

43,507

-282,856

-267,456

-260,156

-291,141

-6,248

-5,787

-5,965

-5,980

4,116

3,155

2,702

2,934

373

373

1,393

372

-15,410

-14,012

-13,920

-15,407

527

-6,064

-8,126

-5,914

-14,843

-10,356

-9,175

-9,109

-704

2

11

11

13

0

0

-

-

0

-

0

0

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Gain on sale of Ibis Biosciences, Inc., net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income from discontinued operations, net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income (loss)

153,898

303,262

402,036

363,239

316,681

214,985

-96,916

-84,044

-30,559

-10,783

5,737

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.

-7,579

9,116

-27,770

-35,844

-42,923

-58,756

-47,660

-36,736

-20,521

-11,129

-4,882

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders

161,477

294,146

429,805

399,083

359,604

273,741

-49,256

-47,308

-10,038

346

55,289

65,251

11,481

-60,400

-183,854

-226,981

-134,478

-88,278

14,208

23,308

-24,421

-38,984

-94,313

-92,207

-90,252

-60,644

-39,005

-52,074

-43,155

-65,478

-82,877

-72,120

-88,802

-84,801

-78,750

-64,322

-71,587

-61,251

-58,848

-49,124

0

0

0

Basic and diluted net loss per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.47

-

-

-

-

-0.14

-

-0.23

-

-0.27

-0.23

-0.21

-0.09

-0.02

-0.03

-0.37

-0.01

-0.24

-0.20

-0.27

-0.18

-0.20

-

-

-

-

-

-

Shares used in computing basic and diluted net loss per share (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

120,798

-

-

-

-

118,948

-

117,811

-

117,128

116,331

115,263

108,539

101,875

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders, Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.12

-0.03

Basic net income per share (in dollars per share)

-0.35

1.31

0.19

-0.01

0.63

2.42

-0.03

-0.29

-0.01

0.12

-0.02

-0.02

0.07

-

0.06

-

-0.52

-

-0.30

0.30

-

-

-

-0.10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.13

-0.25

-0.10

-0.12

-0.03

Shares used in computing basic net income (loss) per share (in shares)

139,429

140,612

140,551

140,247

138,582

137,892

137,346

128,712

125,330

124,844

124,370

123,989

122,861

-

120,989

-

120,598

-

119,979

119,742

-

-

-

117,588

-

-

-

-

-

-

100,680

100,213

100,157

99,766

99,687

99,602

99,569

99,272

99,196

99,091

99,013

98,320

98,116

Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders, Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.12

-0.03

Diluted net income per share (in dollars per share)

-0.35

1.29

0.18

-0.01

0.62

2.40

-0.03

-0.29

-0.01

0.12

-0.02

-0.02

0.07

-

0.06

-

-0.52

-

-0.30

0.29

-

-

-

-0.10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.13

-0.25

-0.10

-0.12

-0.03

Shares used in computing diluted net income (loss) per share (in shares)

139,429

146,296

143,408

140,247

141,537

144,836

137,346

128,712

125,330

131,061

124,370

123,989

124,972

-

123,378

-

120,598

-

119,979

127,779

-

-

-

117,588

-

-

-

-

-

-

100,680

100,213

100,157

99,766

99,687

99,602

99,569

99,272

99,196

99,091

99,013

98,320

98,116

Commercial [Member]
Revenue

368,323

352,450

325,031

312,088

280,987

254,922

235,885

187,746

154,236

120,014

69,184

36,581

28,908

22,767

20,368

18,557

3,312

2,343

3,987

4,049

3,727

11,647

9,922

9,984

10,013

3,091

6,036

6,183

5,906

5,634

2,812

2,862

3,180

2,896

3,158

3,473

5,315

5,552

5,378

4,763

0

0

0

Royalty revenues from the sale of SPINRAZA (nusinersen).
Revenue

299,289

292,992

282,071

270,409

256,560

237,930

219,817

182,697

148,410

112,540

61,350

28,460

6,094

883

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from the sale of TEGSEDI (inotersen).
Revenue

50,658

42,253

30,801

18,856

8,991

2,237

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA.
Revenue

18,376

17,205

12,159

22,823

15,436

14,755

16,068

5,049

5,826

7,474

7,834

8,121

22,814

21,884

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from research and development services performed under a collaboration agreement.
Revenue

590,429

770,149

496,001

486,447

471,482

344,752

339,468

360,526

388,562

394,165

463,708

488,924

422,794

350,009

217,474

157,479

254,682

281,360

313,006

307,886

244,856

202,514

161,626

141,086

122,073

144,194

118,874

106,743

116,268

96,415

111,767

120,829

97,994

96,190

89,945

97,541

94,379

102,921

103,446

106,429

0

0

0